Company / Cash per Share
Viridian Therapeutics, Inc.\DE Cash per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$8.86
FY2024
5-year range
$8.86 / $16.53
FY2020-FY2024
Trend
-16.9%
vs FY2023
Sector context
#23 of 205
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's cash per share of $8.86 is higher than 89% of companies in the Health Care sector (FY2024). Cash per Share has declined for 4 consecutive years, from $35.87 in FY2020 to $8.86 in FY2024.
Based on SEC 10-K filings.
8.86 in FY2024 with a 5-year CAGR of -7.1%. Top quartile in the Health Care sector.
Declined from $13.23 to $8.86 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -18.8%
- 5-Year CAGR
- -7.1%
- 10-Year CAGR
- -
Sector benchmark
-87.9% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's cash per share has declined for 4 consecutive years.
- In FY2024, cash per share decreased 16.9% year-over-year.
- Ranks #23 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $8.86 | -16.9% |
| FY2023 | $10.67 | -19.4% |
| FY2022 | $13.23 | -19.9% |
| FY2021 | $16.53 | -53.9% |
| FY2020 | $35.87 | +179.6% |
| FY2019 | $12.83 | +1064.6% |
| FY2018 | $1.10 | -98.1% |
| FY2017 | $56.90 | +82.5% |
| FY2016 | $31.18 | +455.3% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026